Please assess the completion status of the following clinical trial:

Trial Title: Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged \>50 years.~* Patients with newly diagnosed or relapsing bullous pemphigoid based on clinical diagnosis to be confirmed by direct immunofluorescence and indirect immunofluorescence on salt-spit skin (or BP180 and/or BP230 ELISA). Confirmation by laboratory tests will be obtained ideally before or anyway within one week after enrolment.~For the purpose of this study, clinical relapses are defined as re-appearance of clinical symptoms after the patient had attained remission lasting for more than 3 months without immunosuppressive treatment. In patients with relapsing BP, clinical diagnosis will be confirmed by indirect immunofluorescence or BP180 and/or BP230 ELISA only.~* Patients with mild to moderate active blistering disease (total number of blisters between 1 and 30) whether associated or not with urticarial/eczematous lesions.~* Patients with modified ABSIS score ≤50~* Patients free from any systemic treatments that may affect the course of the disease with the following off-period prior to enrolment:~  1. 3 weeks: steroids, dapsone, tetracyclines, nicotinamide,~ 2. 3 months: azathioprine, mycofenolate mofetil, cyclophosphamide, methotrexate, intravenous immunoglobulins, immunoadsorption, TNF antagonists~ 3. 12 months: rituximab, leflunomide~* Patients free from any topical treatments other than topical antibiotics and antiseptics in the 4 days prior to enrolment.~* Patients able to comply with the protocol procedures for the duration of the study, including scheduled follow-up visits and examinations.~* Patients able to provide informed consent.~Exclusion Criteria:~* Patients with a Karnofsky rating score \<40%.~* Patients with mucosal involvement.~* Patients with moderate to severe renal impairment as per calculated creatinine clearance (CLcr) \< 50 mL/min according to the Cockcroft-Gault formula (Cockcroft-Gault , 1976).~* Patients with hepatic dysfunction defined by increased ALT/AST \> 3 x upper limit of normal (ULN) and increased total bilirubin \> 3 mg/dL \[\>51.3 μmol/L\].~* Patients with hypoalbuminemia defined as serum albumin \< 3 g/dL.~* Patients with a baseline (day 0/1, pre-dose) QTcF \> 470 msec.~* Patients who had a myocardial infarction in the 6 months prior to enrolment.~* Patients on treatment with phenytoin, warfarin, sulphonylurea hypoglycemics (e.g. tolbutamide, glipizide, glibenclamide/glyburide, glimepiride, nateglinide) and high dose of amitriptyline (\> 50 mg/day).~* Patients with known hypersensitivity to non-steroidal antiinflammatory drugs.~* Patients using any investigational agent within 12 months prior to enrolment.~* Pregnant or breast feeding women. Unwillingness to use effective contraceptive measures up to 2 months after the end of study drug administration (females and males).~Additional Exclusion Criteria for Germany only:~* Patients with hypokalemia defined as serum potassium \< 3.5 mmol/L.~* Patients with clinically relevant bradycardia (heart rate \< 50 beats/min)~* Patients with a complete left bundle branch block.~* Patients with a history of uncontrolled or labile hypertension~* Patients with a history of congestive heart failure.~* Patients with a history of cardiomyopathy.~* Patients with unstable angina pectoris.~* Patients with a personal or family history of congenital or documented acquired QT interval prolongation.~* Patients with a significant atrial or ventricular arrhythmia or symptomatic arrhythmia in the past.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DF2156A 150 mg (Type: EXPERIMENTAL): 150 mg capsule twice a day (every 12 h) for a maximum of 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).